Abstract
The aim of this study was to investigate the effect of hexagonal selenium nanoparticles modified by SiRNA (HSNM-SiRNA) to inhibit epidermal growth factor receptor (EGFR) signaling in Human non-small-cell lung cancer (NSCLC). After synthesis, HSNM-SiRNA and HSNs were separately exposed to NSCLC cell lines (A549, H1299, H520, and H1975), and incubated for 6 h at 37 °C. Next, the expression of NFKB, MYC, STAT, ELK1, and GAPDH was evaluated by western blot and real-time PCR. The percentage of apoptotic cells and cell cycle progression were measured when exposed to HSNM-SiRNA and HSNs. Both western blot and real-time PCR results showed that HSNM-SiRNA could down-regulate the expression of all EGFR signaling genes. The percentage of apoptotic cells was significantly increased in all cell lines when exposed to HSNM-SiRNA (P>0.05). HSNM-SiRNA in A549 and H1299 cells significantly increased the proportion of cells in G1/G0 phase and significantly decreased the proportion of cells in S phase.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Herbst RS . Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology* Biology* Physics 2004; 59: S21–S26.
Oda K, Matsuoka Y, Funahashi A, Kitano H . A comprehensive pathway map of epidermal growth factor receptor signaling. Molecular systems biology 2005; 1: 2005.
Schoeberl B, Eichler-Jonsson C, Gilles ED, Müller G . Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nature biotechnology 2002; 20: 370–375.
Perona R . Cell signalling: growth factors and tyrosine kinase receptors. Clinical and Translational Oncology 2006; 8: 77–82.
Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, Ramalingam SS et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American society of clinical oncology endorsement of the college of american pathologists/international society for the study of lung cancer/association of molecular pathologists guideline. Journal of Clinical Oncology 2014: JCO 2014; 57: 3055.
Reddy RJ, Gajadhar AS, Swenson EJ, Rothenberg DA, Curran TG, White FM . Early signaling dynamics of the epidermal growth factor receptor. Proceedings of the National Academy of Sciences 2016; 113: 3114–3119.
Helena AY, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clinical cancer research 2013; 19: 2240–2247.
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532–536.
Hynes NE, Ingham PW, Lim WA, Marshall CJ, Massagué J, Pawson T . Signalling change: signal transduction through the decades. Nature Reviews Molecular Cell Biology 2013; 14: 393–398.
Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. The Journal of clinical investigation 2008; 118: 2609–2619.
Makinoshima H, Takita M, Matsumoto S, Yagishita A, Owada S, Esumi H et al. Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma. Journal of Biological Chemistry 2014; 289: 20813–20823.
Coxam B, Neyt C, Grassini DR, Le Guen L, Smith KA, Schulte‐Merker S et al. carbamoyl‐phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (cad) regulates Notch signaling and vascular development in zebrafish. Developmental Dynamics 2015; 244: 1–9.
Singh N, Agrawal A, Leung AK, Sharp PA, Bhatia SN . Effect of nanoparticle conjugation on gene silencing by RNA interference. Journal of the American Chemical Society 2010; 132: 8241–8243.
Harris RC, Chung E, Coffey RJ . EGF receptor ligands The EGF receptor family biologic mechanisms and role in cancer. Elsevier: California, 2004: 3–14.
Schlessinger J . Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002; 110: 669–672.
Huang S-M, Li J, Armstrong EA, Harari PM . Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer research 2002; 62: 4300–4306.
Pourdanesh F, Jebali A, Hekmatimoghaddam S, Allaveisie A . In vitro and in vivo evaluation of a new nanocomposite, containing high density polyethylene, tricalcium phosphate, hydroxyapatite, and magnesium oxide nanoparticles. Materials Science and Engineering: C 2014; 40: 382–388.
Barkhordari A, Barzegar S, Hekmatimoghaddam H, Jebali A, Moghadam SR, Khanjani N . The toxic effects of silver nanoparticles on blood mononuclear cells. The international journal of occupational and environmental medicine 2014; 5: 394–164-8.
Jebali A, Hekmatimoghaddam S, Kazemi B . The cytotoxicity of silver nanoparticles coated with different free fatty acids on the Balb/c macrophages: an in vitro study. Drug and chemical toxicology 2014; 37: 433–439.
Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2–16.
Lo H-W, Hsu S-C, Hung M-C . EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast cancer research and treatment 2006; 95: 211–218.
Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors potential therapy for cancer. Cancer Research 2001; 61: 7196–7203.
Politi K, Ayeni D, Lynch T . The next wave of EGFR tyrosine kinase inhibitors enter the clinic. Cancer cell 2015; 27: 751–753.
Lee CK, Wu Y-L, Ding PN, Lord SJ, Inoue A, Zhou C et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. Journal of Clinical Oncology 2015; 33: 1958–1965.
Acknowledgements
The authors thank the laboratory staff of paramedicine medical research center and Department of Developmental Cell Biology, School of Biological Sciences, Azad University, Tehran North Branch, Tehran, Iran. This article was founded by KAJED RESEARCH CENTER, grant number: 2016-69.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Kamrani Moghaddam, L., Ramezani Paschepari, S., Zaimy, M. et al. The inhibition of epidermal growth factor receptor signaling by hexagonal selenium nanoparticles modified by SiRNA. Cancer Gene Ther 23, 321–325 (2016). https://doi.org/10.1038/cgt.2016.38
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2016.38
This article is cited by
-
Nanoselenium attenuates renal ischemia-reperfusion injury in rats
Naunyn-Schmiedeberg's Archives of Pharmacology (2023)
-
A Review of Solid Electrolyte Interphase (SEI) and Dendrite Formation in Lithium Batteries
Electrochemical Energy Reviews (2023)
-
Morphology, structural and microstructural characterizations of mechanically alloyed Fe50Co40Ni10 powder mixture
Applied Physics A (2022)